Irritable bowel syndrome

Newer pharmacological agents acting on the gut

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The objectives of this brief review are to provide an update on the clinical pharmacology and clinical trials of new potential therapies for irritable bowel syndrome (IBS). These medications include: 5-HT3 antagonists, 5-HT4 agonists, α2-adrenergic agonists, κ opioid agonists, neurokinin antagonists, neostigmine, probiotics and antibiotics. While these approaches offer promise and a substantial rationale based on modulating the brain gut axis, the potential for central effects and the clinical efficacy of some of these agents are still being explored, and proof of concept studies needs to be supported by robust evidence of positive risk–benefit.

Original languageEnglish (US)
Pages (from-to)143-148
Number of pages6
JournalInternational Congress Series
Volume1241
Issue numberC
DOIs
StatePublished - Sep 1 2002

Fingerprint

Serotonin 5-HT4 Receptor Agonists
Serotonin 5-HT3 Receptor Antagonists
Neostigmine
Adrenergic Agonists
Clinical Pharmacology
Irritable Bowel Syndrome
Probiotics
Opioid Analgesics
Clinical Trials
Pharmacology
Anti-Bacterial Agents
Brain
Therapeutics

Keywords

  • Clonidine
  • IBS
  • Neurokinin
  • Probiotics
  • Serotonin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Irritable bowel syndrome : Newer pharmacological agents acting on the gut. / Camilleri, Michael.

In: International Congress Series, Vol. 1241, No. C, 01.09.2002, p. 143-148.

Research output: Contribution to journalArticle

@article{869c1d07c730477eb502607941fecaae,
title = "Irritable bowel syndrome: Newer pharmacological agents acting on the gut",
abstract = "The objectives of this brief review are to provide an update on the clinical pharmacology and clinical trials of new potential therapies for irritable bowel syndrome (IBS). These medications include: 5-HT3 antagonists, 5-HT4 agonists, α2-adrenergic agonists, κ opioid agonists, neurokinin antagonists, neostigmine, probiotics and antibiotics. While these approaches offer promise and a substantial rationale based on modulating the brain gut axis, the potential for central effects and the clinical efficacy of some of these agents are still being explored, and proof of concept studies needs to be supported by robust evidence of positive risk–benefit.",
keywords = "Clonidine, IBS, Neurokinin, Probiotics, Serotonin",
author = "Michael Camilleri",
year = "2002",
month = "9",
day = "1",
doi = "10.1016/S0531-5131(02)00630-1",
language = "English (US)",
volume = "1241",
pages = "143--148",
journal = "International Congress Series",
issn = "0531-5131",
publisher = "Elsevier BV",
number = "C",

}

TY - JOUR

T1 - Irritable bowel syndrome

T2 - Newer pharmacological agents acting on the gut

AU - Camilleri, Michael

PY - 2002/9/1

Y1 - 2002/9/1

N2 - The objectives of this brief review are to provide an update on the clinical pharmacology and clinical trials of new potential therapies for irritable bowel syndrome (IBS). These medications include: 5-HT3 antagonists, 5-HT4 agonists, α2-adrenergic agonists, κ opioid agonists, neurokinin antagonists, neostigmine, probiotics and antibiotics. While these approaches offer promise and a substantial rationale based on modulating the brain gut axis, the potential for central effects and the clinical efficacy of some of these agents are still being explored, and proof of concept studies needs to be supported by robust evidence of positive risk–benefit.

AB - The objectives of this brief review are to provide an update on the clinical pharmacology and clinical trials of new potential therapies for irritable bowel syndrome (IBS). These medications include: 5-HT3 antagonists, 5-HT4 agonists, α2-adrenergic agonists, κ opioid agonists, neurokinin antagonists, neostigmine, probiotics and antibiotics. While these approaches offer promise and a substantial rationale based on modulating the brain gut axis, the potential for central effects and the clinical efficacy of some of these agents are still being explored, and proof of concept studies needs to be supported by robust evidence of positive risk–benefit.

KW - Clonidine

KW - IBS

KW - Neurokinin

KW - Probiotics

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=70349284008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349284008&partnerID=8YFLogxK

U2 - 10.1016/S0531-5131(02)00630-1

DO - 10.1016/S0531-5131(02)00630-1

M3 - Article

VL - 1241

SP - 143

EP - 148

JO - International Congress Series

JF - International Congress Series

SN - 0531-5131

IS - C

ER -